share_log

Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates

Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates

Xencor，加州大學洛杉磯分校(UCLA)針對XmAb候選治療的墨水合作協定
Benzinga Real-time News ·  2021/02/25 20:15
  • Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor's modular suite of XmAb technology platforms. 
  • Xencor's XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures. Xencor and its pharmaceutical partners are now advancing 20 clinical-stage XmAb-engineered drug candidates to treat various life-threatening and debilitating diseases.
  • UCLA will work to propose potential antibody drug candidates. The collaborators will use a framework with predefined terms to enter sponsored research agreements and potential license agreements for selected candidates.
  • Price Action: XNCR closed 0.3% higher at $48.5 on Wednesday.
  • Xencor Inc.(納斯達克：XNCR)和加州大學洛杉磯分校技術開發集團(UCLA Technology Development Group)同意開發採用Xencor模塊化XmAb技術平台的新型治療性抗體。
  • Xencor的XmAb平台是精確設計的抗體Fc結構域，能夠創建穩定的新蛋白質結構。Xencor及其製藥合作伙伴現在正在推進20種臨牀階段的XmAb工程藥物候選藥物，用於治療各種威脅生命和虛弱的疾病。
  • 加州大學洛杉磯分校(UCLA)將致力於提出潛在的抗體藥物候選方案。合作者將使用一個帶有預定義條款的框架，為選定的候選人輸入贊助研究協議和潛在的許可協議。
  • 價格行動：XNCR週三收高0.3%，報48.5美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論